Navigation Links
N30 Pharma Announces Financing, Expansion of Board
Date:10/28/2008

BOULDER, Colo., Oct. 28 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that regulate nitric oxide bioavailability, announced today that it has completed a financing and expanded its Board of Directors.

N30 will use proceeds from this financing to advance its clinical program in Cystic Fibrosis and expand its discovery and preclinical research in the area of small molecule drugs that modulate nitric oxide bioavailability in cardiopulmonary diseases. The financing is the company's second since its formation in 2007. Joining the company's Board of Directors are Arnold Snider and Marc Elia. Mr. Snider will assume the role of Chairman of the Board.

Mr. Snider previously founded and managed Deerfield Management, a New York-based multi-billion dollar hedge fund focused on healthcare and life-sciences companies. Mr. Snider is also on the Board of Directors of the Christopher and Dana Reeve Foundation and is a trustee of Davidson College.

Mr. Elia co-founded N30 while at Tiger Management, a New York hedge fund, and has had previous roles in life sciences corporate strategy at Chiron Corporation and L.E.K. Consulting.

"I am pleased with our investors' ongoing commitment to the major clinical potential of N30 Pharma, particularly in difficult economic times. In addition, I welcome Arnie and Marc to their roles on the Board. Arnie is widely regarded as one of the premier healthcare investors in the world. Marc brings a multitude of talents and intellect to the N30 Board. I look forward to drawing on their expertise and long experience with biopharmaceutical companies as we continue to move N30 forward," commented Charles Scoggin, M.D., President and CEO of N30.

About N30 Pharma

N30 Pharma is a clinical-stage company developing s-nitrosothiol therapies for major unmet needs in cardiopulmonary diseases. S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone and inflammatory responses. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
7. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
11. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) today announced that its Board of ... of the company,s common stock. This program will became ... 2017. Purchases may be made in the open market, ... time to time as determined by United Therapeutics, management ...
(Date:4/27/2017)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive ... a rare devastating genetic disease that leads to a sudden and rapid loss of ... patients carrying 11778, 14484 and 3460 mutations and having experienced the onset of symptoms ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the ... review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn ... 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, ...
(Date:4/27/2017)... USA (PRWEB) , ... April 27, 2017 , ... ... optics and photonics , joined other scientists, researchers, engineers, and industry professionals in ... to strengthen America's ability to compete in the world photonics industry. , This ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):